姜黄素-胡椒碱共补充对COVID-19患者临床体征、病程、严重程度及炎症因子的影响:随机对照试验研究方案的结构化摘要
本试验旨在研究姜黄素-胡椒碱共补充对COVID-19患者病程、严重程度、临床症状及炎症介质的效果。采用随机、安慰剂对照、双盲、平行组设计,计划纳入100例20-75岁经PCR确诊的患者,干预组每日两次服用含500mg姜黄素和5mg胡椒碱的胶囊,对照组服用安慰剂,持续2周。主要结局为干预2周后临床症状、病程、严重程度及炎症介质的变化。
要点
- 姜黄素-胡椒碱共补充可能影响COVID-19病程和炎症反应,尚待试验验证。
- 试验纳入门诊和住院(非ICU)患者,干预为期2周。
- 主要结局包括临床症状、病程、严重程度及炎症介质。
核心结论
- 本试验旨在评估姜黄素-胡椒碱共补充对COVID-19患者病程、严重程度、临床症状及炎症介质的效果,结果尚未报告。
研究设计与样本
- 随机、安慰剂对照、双盲、平行组临床试验,计划纳入100例20-75岁经PCR确诊的COVID-19患者。
- 50例门诊患者和50例住院(非ICU)患者分别按1:1随机分配至干预组或对照组。
- 随机序列采用随机数字表生成,置换区组设计(区组大小4),按性别分层,分配隐藏于不透明密封编号信封中。
- 干预组每日两次(午餐和晚餐后)服用含500mg姜黄素和5mg胡椒碱的胶囊,对照组服用含505mg麦芽糊精的匹配安慰剂,持续2周。
- 研究在伊朗伊斯法罕医科大学附属学术医院进行,招募始于2020年5月4日,预计2021年4月19日完成。
关键数值与推荐
- 主要结局为干预2周后临床症状、病程、严重程度及炎症介质的变化。
- 纳入标准:年龄20-75岁,经PCR检测确诊COVID-19。
- 排除标准:年龄小于20岁或大于75岁,当前使用华法林或其他抗凝药物,对姜黄、胡椒等草药产品过敏。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aims to investigate the efficacy of curcumin-piperine co-supplementation on disease duration, severity and clinical symptoms, and inflammatory mediators in patients with coronavirus (COVID-19). TRIAL DESIGN: This is a randomized, placebo-controlled, double-blind, parallel arm clinical trial. PARTICIPANTS: All patients aged 20-75 years with the diagnosis of Covid-19 based on the PCR test. The exclusion criteria will include an age less than 20 and more than 75 years, current use of warfarin or other anticoagulant drugs, and the presence of sensitivity to herbal products such as turmeric and pepper. This study will be conducted in academic hospitals affiliated to Isfahan University of Medical Sciences, Isfahan, Iran. INTERVENTION AND COMPARATOR: Fifty outpatients will be randomly allocated in a ratio of 1:1 to receive a capsule of curcumin-piperine containing 500 mg curcumin plus 5 mg piperine or matching placebo containing 505 mg maltodextrin twice a daily, after lunch and dinner, over a period of 2 weeks. Similarly, 50 inpatients who are admitted to hospital wards excluding intensive care unit (ICU) will be randomly assigned in a ratio of 1:1 to receive a capsule curcumin-piperine or matching placebo (provided by the Sami Labs company) twice a daily, after lunch and dinner, over a period of 2 weeks. MAIN OUTCOMES: The main outcomes of this study are the efficacy of curcumin-piperine on coronavirus disease's clinical symptoms, duration, severity, and inflammatory mediators after 2 weeks of curcumin-piperine co-supplementation. RANDOMISATION: Randomization sequences will be generated with the use of a random-number table with a permuted block design (block size of 4) and stratification according to the gender variable (male vs. female). These sequences will be prepared by an independent statistician and will be kept in opaque, sealed, numbered envelopes which will be opened only at the time of enrollment. The allocation ratio in intervention and control groups is 1:1. Researchers and all patients will be unaware of the study-group assignment until the completion of data analyses. BLINDING (MASKING): This study is a double-blind clinical trial (participant, researcher). The curcumin-piperine and placebo supplements are packaged in similar numbered drug containers, and the researcher and all patients will be unaware of the study assignment until the end of the study. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): The calculated total sample size is 100 patients, with 25 patients in each group. TRIAL STATUS: The protocol is Version 2.0, May 24, 2020. Recruitment began May 4, 2020, and is anticipated to be completed by April 19, 2021. TRIAL REGISTRATION: This trial has been registered by the title of "Effect of curcumin-piperine co-supplementation on disease duration, severity and clinical signs, and inflammatory factors in patients with coronavirus (COVID-19): A randomized, double-blind, placebo-controlled clinical trial study" in the Iranian Registry of Clinical Trials (IRCT) with code "IRCT20121216011763N46", https://www.irct.ir/trial/47529 . The registration date is May 4, 2020. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
引用
- Miryan M, Bagherniya M, Sahebkar A, et al. Effects of curcumin-piperine co-supplementation on clinical signs, duration, severity, and inflammatory factors in patients with COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials. 2020. PMID: 33334357. doi:10.1186/s13063-020-04924-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。